Department of Internal Medicine, Corewell Health/Michigan State University, 100 Michigan St NE, Grand Rapids, MI, 49503, USA.
Division of Cardiology, Department of Medicine, Duke University School of Medicine, 2301 Erwin Road, Durham, NC, 27710, USA.
Curr Atheroscler Rep. 2024 Aug;26(8):341-351. doi: 10.1007/s11883-024-01214-6. Epub 2024 May 29.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are gaining importance due to their effects on cardiovascular parameters. This review discusses the findings of dedicated cardiovascular outcome trials of GLP-1RAs and summarizes their utility to help clinicians understand their role in cardiovascular disease.
Patients with diabetes mellitus are at an increased risk of cardiovascular disease. Cardiovascular outcome trials have shown GLP-1RAs decrease the primary composite outcome of the first occurrence of major adverse cardiovascular events (MACE) in patients with diabetes. Additionally, select GLP-1RAs have also shown improved cardiovascular outcomes in patients without diabetes who are either overweight (BMI ≥ 27), or obese (BMI ≥ 30). There have also been encouraging results in patients with heart failure with preserved ejection fraction. There is increasing evidence showing GLP-1RAs are beneficial across the cardiometabolic spectrum of disease. Implementation of these therapeutics into clinical practice is important to improve cardiovascular risk.
胰高血糖素样肽-1 受体激动剂（GLP-1RAs）因其对心血管参数的影响而受到重视。这篇综述讨论了专门的 GLP-1RA 心血管结局试验的结果，并总结了它们的用途，以帮助临床医生了解它们在心血管疾病中的作用。
糖尿病患者患心血管疾病的风险增加。心血管结局试验表明，GLP-1RAs 可降低糖尿病患者首次发生主要不良心血管事件（MACE）的主要复合结局。此外，一些 GLP-1RAs 还显示出在超重（BMI≥27）或肥胖（BMI≥30）且无糖尿病的患者中改善了心血管结局。在射血分数保留的心力衰竭患者中也取得了令人鼓舞的结果。越来越多的证据表明 GLP-1RAs 在整个心脏代谢疾病谱中是有益的。将这些治疗方法应用于临床实践对于改善心血管风险非常重要。
